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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to 
SYNBIO
®
, a combination of Lactobacillus rhamnosus IMC 501
®
 and 
Lactobacillus paracasei IMC 502
®
, and maintenance of normal defecation 
pursuant to Article 13(5) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Synbiotec S.r.l., submitted for authorisation of a health claim pursuant to 
Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the EFSA Panel on 
Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation 
of a health claim related to SYNBIO
®
, a combination of Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus 
paracasei IMC 502
®
, and maintenance of normal defecation. The Panel considers that the food, SYNBIO
®
, 
which is the subject of the health claim, is sufficiently characterised. Maintenance of normal defecation is a 
beneficial physiological effect. The applicant identified three human intervention studies which investigated the 
effect of SYNBIO
®
 on outcome measures (i.e. frequency of defecations, faecal bulk and stool consistency) 
related to the claimed effect. The Panel notes that no evidence was provided that the tools used to assess changes 
in bowel habits in response to an intervention were valid. Therefore, no conclusions could be drawn from these 
studies for the scientific substantiation of a claim on SYNBIO
®
 and maintenance of normal defecation. In the 
absence of evidence for an effect of SYNBIO
®
 on the maintenance of normal defecation in humans, studies 
which investigated the presence of L. rhamnosus IMC 501
®
 and L. paracasei IMC 502
®
 in the faeces of 
participants who consumed foods enriched with these strains were not considered by the Panel. The Panel 
concludes that a cause and effect relationship has not been established between the consumption of SYNBIO
®
 
and maintenance of normal defecation. 




, Lactobacillus rhamnosus IMC 501
®
, Lactobacillus paracasei IMC 502
®
, defecation, health claims 
                                                     
1 On request from the Competent Authority of Italy following an application by Synbiotec S.r.l., Question No EFSA-Q-
2014-00567, adopted on 22 April 2015. 
2 Panel members: Carlo Agostoni, Roberto Berni Canani, Susan Fairweather-Tait, Marina Heinonen, Hannu Korhonen, 
Sébastien La Vieille, Rosangela Marchelli, Ambroise Martin, Androniki Naska, Monika Neuhäuser-Berthold, Grażyna 
Nowicka, Yolanda Sanz, Alfonso Siani, Anders Sjödin, Martin Stern, Sean (J.J.) Strain, Inge Tetens, Daniel Tomé, 
Dominique Turck and Hans Verhagen. In line with EFSA’s policy on declarations of interest, Panel member Anders 
Sjödin did not participate in the development and adoption of this scientific output. Correspondence: nda@efsa.europa.eu 
3 Acknowledgement: The Panel wishes to thank the members of the Working Group on Claims: Carlo Agostoni, Jean-Louis 
Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Hildegard Przyrembel, Yolanda Sanz, Alfonso 
Siani, Sean (J.J.) Strain, Inge Tetens, Hendrik Van Loveren, Hans Verhagen and Peter Willatts, for the preparatory work 
on this scientific opinion. 
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SUMMARY 
Following an application from Synbiotec S.r.l., submitted for authorisation of a health claim pursuant 
to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Italy, the EFSA 
Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the 
scientific substantiation of a health claim related to SYNBIO
®
, a combination of Lactobacillus 
rhamnosus IMC 501
®
 and Lactobacillus paracasei IMC 502
®
, and maintenance of normal defecation. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The food that is the subject of the health claim is SYNBIO
®
, a combination (1:1) of two bacterial 
strains, Lactobacillus rhamnosus IMC 501
®





available in the form of a lyophilised powder to be added to foods or used as a dietary supplement. 
The identification and characterisation of the strains at species and strain levels have been performed 
by applying appropriate phenotypic and genotypic methods. The Panel considers that the food, 
SYNBIO
®
, which is the subject of the health claim, is sufficiently characterised. 
The claimed effect proposed by the applicant is “favouring the natural regularity and contributing to 
maintain and improve human intestinal well-being”. The target population proposed by the applicant 
is the healthy adult population. Upon a request by EFSA for clarification of the claimed effect, the 
applicant indicated that the claimed effect is maintenance of normal defecation and the outcome 
measures to substantiate the claimed effect were “intestinal regularity” (i.e. stool frequency), stool 
volume and stool consistency. The Panel considers that maintenance of normal defecation is a 
beneficial physiological effect. 
The applicant identified three human intervention studies which investigated the effect of SYNBIO
®
 
on outcome measures (i.e. frequency of defecations, faecal bulk and stool consistency) related to the 
claimed effect.  
In these double-blind, placebo-controlled parallel intervention studies, healthy adults were 
randomised to consume daily food portions enriched with SYNBIO
® 
or capsules of SYNBIO
®
 or their 
corresponding placebos (same food or capsules without SYNBIO
®
) for 12 weeks.  
In these studies, participants were asked to record daily the number of defecations and the number of 
“stool eggs” (used as a surrogate measure for stool volume). In two of the three studies, participants 
were also asked to assess daily stool consistency using the Bristol Stool Scale. At the end of each 
study period, participants were asked to self-evaluate how their bowel habits had changed, compared 
with the period before the interventions, by completing questionnaires which were based on Likert 
scales. In one study, a questionnaire based on a Bristol Stool Scale was used by the participants to 
self-evaluate changes in stool consistency at the end of the study period. Only results of the statistical 
analyses of the Likert scale scores and the Bristol Stool Scale values (in one study), which were 
obtained at the end of the study periods, were provided. 
The Panel notes that no evidence was provided by the applicant that the Likert scales or the Bristol 
Stool Scale, as used in the three studies mentioned above, are valid tools for assessing changes in 
bowel habits in response to an intervention (i.e. on their ability to yield consistent and reproducible 
estimates of changes in bowel habits over time), and thus it is unclear how the outcome measures 
derived from these assessments  relate to the claimed effect (i.e. maintenance of normal defecation).  
The Panel considers that no conclusions can be drawn from these studies for the scientific 
substantiation of a claim on SYNBIO
®
 and maintenance of normal defecation. 
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In the absence of evidence for an effect of SYNBIO
®
 on the maintenance of normal defecation in 
humans, studies which investigated the presence of L. rhamnosus IMC 501
®
 and L. paracasei IMC 
502
®
 in the faeces of participants who consumed foods enriched with these strains were not 
considered by the Panel.  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of SYNBIO
®
, a combination of Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus 
paracasei IMC 502
®






and maintenance of normal defecation 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
of disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 06/08/2014. 
 The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
 On 11/09/2014, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 26/09/2014, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 31/10/2014. 
 On 26/11/2014, the Working Group on Claims of the NDA Panel agreed on a list of questions 
for the applicant to provide additional information to accompany the application. The 
scientific evaluation was suspended on 09/12/2014 and was restarted on 24/12/2014, in 
compliance with Article 18(3) of Regulation (EC) No 1924/2006. 
 On 05/01/2015, EFSA received the requested information (which was made available to 
EFSA in electronic format on 30/12/2014). 
 On 06/02/2015, the NDA Panel agreed on a list of questions for the applicant to provide 
additional information to accompany the application. The scientific evaluation was suspended 
on 11/02/2015, in compliance with Article 18(3) of Regulation (EC) No 1924/2006. On 
26/02/2015, EFSA received the requested information and the scientific evaluation was 
restarted. 
 During its meeting on 22/04/2015, the NDA Panel, having evaluated the data, adopted an 
opinion on the scientific substantiation of a health claim related to SYNBIO
®
, a combination 
of Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus paracasei IMC 502
®
, and 
maintenance of normal defecation.  
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with 
Article 16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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opinion on the scientific substantiation of a health claim related to: SYNBIO
®
, a combination of 
Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus paracasei IMC 502
®
, and maintenance of 
normal defecation. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of SYNBIO
®
, a combination of Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus 
paracasei IMC 502
®
, a positive assessment of its safety, nor a decision on whether SYNBIO
®
 is, or is 
not, classified as a foodstuff. It should be noted that such an assessment is not foreseen in the 
framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address 
Synbiotec S.r.l. Via Gentile III da Varano, 62032, Camerino (MC), Italy. 
The application includes a request for the protection of proprietary data for the two bacterial strains 
and some information pertaining to their characterisation, in accordance with Article 21 of 
Regulation (EC) No 1924/2006. 
Food/constituent as stated by the applicant 
According to the applicant, SYNBIO
®
 is a combination (1:1) of two probiotic bacterial strains 
Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus paracasei IMC 502
®
, in the form of a 
lyophilised powder to be added to functional foods or used, alone or in combination with other 
ingredients, as a dietary supplement. 
Health relationship as claimed by the applicant 
According to the applicant, by consuming probiotic functional foods enriched with SYNBIO
®
 or 
dietary supplements composed of SYNBIO
®
, consumers will obtain the effect of a persistence of two 
probiotic bacterial strains Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus paracasei IMC 
502
®
, in the intestinal tract which will favour natural regularity and contribute to maintaining and 
improving human intestinal well-being. The primary outcome measures used were intestinal regularity 
and increased stool volume. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “SYNBIO® persists in the 
intestinal tract and favours the natural regularity contributing to maintain and improve human 
intestinal well-being”. 
Specific conditions of use as proposed by the applicant 
The target population proposed by the applicant is the healthy adult population. 
The applicant has proposed a daily intake of SYNBIO
® 
of at least 10
9
 colony-forming units (CFU). 
This can be obtained by consuming foods (i.e. yoghurt, “ricotta” cheese, “mozzarella” cheese, 




per 100 g of 




1. Characterisation of the food/constituent 
The food that is the subject of the health claim is SYNBIO
®
, a combination (1:1) of two bacterial 
strains, Lactobacillus rhamnosus IMC 501
®





available in the form of a lyophilised powder to be added to foods or used as a dietary supplement. 
The two bacterial strains, Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus paracasei 
IMC 502
®
, were isolated from the faeces of healthy elderly people (Silvi et al., 2003). The strains 
were identified and characterised by applying appropriate phenotypic and genotypic methods. The 
genotypic methods applied included sequence analysis of the 16S rRNA gene and RAPD analysis for 
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species and strain identification, respectively (Verdenelli et al., 2009). The characterisation of the 
strains has also been published in patents (Cresci et al., 2004, 2005) and it is also described in an 
unpublished PhD thesis (Verdenelli, 2007).  
The strains were deposited in the DSMZ (Deutsche Sammlung von Mikroorganismen und 
Zellkulturen) culture collection, Germany, and have the following deposition numbers: DSM 16104 
and DSM 16105. The DSMZ has been nominated as an International Depositary Authority under the 
Budapest Treaty. 
The applicant provided data on the stability of the strains and their effects on the chemical-physical 
and organoleptic parameters of the foods (i.e. ice-cream, chocolate mousse, chocolate bars, 
mozzarella, ricotta and yoghurt) to which they were added. 
The Panel considers that the food, SYNBIO
®
, a combination of Lactobacillus rhamnosus IMC 501
®
 
and Lactobacillus paracasei IMC 502
®
, which is the subject of the health claim, is sufficiently 
characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “favouring the natural regularity and contributing to 
maintain and improve human intestinal well-being”. The target population proposed by the applicant 
is the healthy adult population.  
Upon a request by EFSA for clarification of the claimed effect, the applicant indicated that the 
claimed effect is maintenance of normal defecation and the outcome measures to substantiate the 
claimed effect were “intestinal regularity” (i.e. stool frequency), stool volume and stool consistency. 
Constipation is associated with less frequent defecations, with reduced faecal bulk and/or harder 
stools, or both. Constipation leads to gastrointestinal discomfort and may contribute to the 
development of, for example, diverticular disease. More frequent defecations through, for example, a 
reduction in transit time, increased faecal bulk and softer stools, may contribute to the maintenance of 
normal defecation, provided that this does not result in diarrhoea.  
The Panel considers that maintenance of normal defecation is a beneficial physiological effect. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed, Scopus and ISI Web of Knowledge using, as 
search terms, “Lactobacillus rhamnosus IMC 501”, “Lactobacillus paracasei IMC 502” and 
“SYNBIO” to identify pertinent human data. Publications related to strains other than Lactobacillus 
rhamnosus IMC 501 and Lactobacillus paracasei IMC 502, as well as those not related to bowel 
habits or bowel function, were excluded. 
The applicant identified three human intervention studies which investigated the effect of SYNBIO
®
 
on outcome measures (i.e. frequency of defecations, faecal bulk and stool consistency) related to the 
claimed effect (Verdenelli et al., 2011a, b; Silvi et al., 2014). 
In the double-blind, placebo-controlled parallel intervention study by Verdenelli et al. (2011a), 
50 healthy adults (aged 23–65 years, 27 females) were randomised to consume daily at least one food 
portion (80–120 g of yoghurt, “ricotta” cheese, “mozzarella” cheese, chocolate, chocolate mousse or 




CFU per serving; n = 25) or placebo (same food 
without SYNBIO
®
; n = 25) for 12 weeks.  
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Upon a request by EFSA for clarification of the outcome measures assessed in the study and the 
methods of measurement, the applicant indicated that the primary outcome measures were “intestinal 
regularity” (i.e. stool frequency) and stool volume, which were recorded daily by the participants as 
the number of defecations (i.e. stool frequency) and the number of “stool eggs” (used as a surrogate 
measure for stool volume). At the end of the study, participants were also asked to self-evaluate how 
stool frequency and stool volume had changed, compared with the period before the intervention, by 
completing a questionnaire which used a Likert scale. Only the statistical analysis of the Likert scale 
scores, which were obtained at the end of the study, was provided. The Panel notes that changes in 
stool frequency and stool volume from baseline, using data recorded daily by the participants, were 
not reported.   
In the double-blind, placebo-controlled, parallel intervention study by Verdenelli et al. (2011b) 





CFU/capsule; n = 80) or placebo (maltodextrin; n = 80) for 12 weeks.  
Upon a request by EFSA for clarification of the outcome measures assessed in the study and the 
methods of measurement, the applicant indicated that stool frequency, stool volume, stool consistency 
and cold symptoms were the primary outcomes of this study. Ease of defecation, 
borborygmi/rumbling stomach, bloating, flatulence, constipation, diarrhoea, abdominal pain and 
intestinal cramps were among the secondary outcome measures investigated in the study. Participants 
were asked to record daily the number of defecations and the number of “stool eggs” of an 
approximated size represented in a graph (used as a surrogate measure for stool volume). Stool 
consistency was assessed daily by the participants using the Bristol Stool Scale. At the end of the 
study, participants were also asked to self-evaluate how stool frequency, stool volume and stool 
consistency had changed, compared with the period before the intervention, by completing a 
questionnaire which used a Likert scale. Only the statistical analysis of the Likert scale scores, which 
were obtained at the end of the study, was provided. The Panel notes that changes in stool frequency, 
stool volume and stool consistency from baseline, using data recorded daily by participants, were not 
reported.  
In the double-blind, placebo-controlled, parallel intervention study by Silvi et al. (2014), 862 healthy 
adults (aged 18–65 years, 470 females) were randomised to consume daily at least one food portion 
(80–120 g) enriched with SYNBIO® (about 109 CFU per serving; n = 217), one capsule of SYNBIO® 
(about 10
9 
CFU/capsule; n = 213), or their corresponding placebos (i.e. same food or capsules without 
SYNBIO
®
; n = 213 in the placebo food group and n = 219 in the placebo capsule group) for 12 weeks.  
Upon a request by EFSA for clarification of the outcome measures assessed in the study and the 
methods of measurement, the applicant indicated that stool frequency and stool volume were the 
primary outcomes of this study, whereas stool consistency was a secondary outcome. Participants 
were asked to record daily the number of defecations and the number of “stool eggs” of an 
approximated size represented in a graph (used as a surrogate measure for stool volume). Stool 
consistency was assessed daily by the participants using the Bristol Stool Scale. At the end of the 
study, participants were asked to self-evaluate how stool frequency and stool volume had changed, 
compared with the period before the intervention, by completing a questionnaire which used a Likert 
scale. At the end of the study, participants were also asked to self-evaluate changes in stool 
consistency by using the Bristol Stool Scale. A comparison of “mean values” of the Bristol Stool 
Scale between groups was presented in the statistical analysis. Upon a request by EFSA for 
clarification on how the “mean values” of the Bristol Stool Scale were calculated, the applicant 
indicated that “mean values” for each group were calculated from the single values obtained in each 
subject at the end of the study period. Only the statistical analyses of the Likert scale scores (stool 
frequency and stool volume) and the Bristol Stool Scale (stool consistency) values obtained at the end 
of the study were provided. The Panel notes that changes in stool frequency, stool volume and stool 
consistency from baseline, using data recorded daily by the participants, were not reported. 
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In relation to the studies described above (Verdenelli et al., 2011a, b; Silvi et al., 2014), EFSA 
requested the applicant to clarify whether the Likert-scale-based questionnaires and the Bristol Stool 
Scale, as used in these studies, were validated to assess changes in bowel habits over time. No 
information was provided by the applicant on how these scales, as used, were validated to quantify 
changes in stool frequency, stool volume and/or stool consistency over time.  
EFSA also requested the applicant to clarify the reason for not using the data (i.e. number of 
defecations, number of “stool eggs” and stool consistency) recorded daily by the participants to assess 
changes in bowel habits over time. The applicant indicated that “the interest of the study was to assess 
whether the participants felt better or worse at the end of the intervention, and did not want to know 
the daily change”.  
The Panel notes that no evidence was provided by the applicant that the Likert scales or the Bristol 
Stool Scale, as used in the studies above, are valid tools for assessing changes in bowel habits in 
response to an intervention (i.e. on their ability to yield consistent and reproducible estimates of 
changes in bowel habits over time), and thus it is unclear how the outcome measures derived from 
these assessments relate to the claimed effect (i.e. maintenance of normal defecation).  
The Panel also notes that inadequate information was provided on how power calculations were 
performed in two of the studies (Verdenelli et al., 2011a, b). 
The Panel considers that no conclusions can be drawn from the three studies described above for the 
scientific substantiation of a claim on SYNBIO
®
 and maintenance of normal defecation. 
In the absence of evidence for an effect of SYNBIO
®
 on the maintenance of normal defecation in 
humans, studies which investigated the presence of L. rhamnosus IMC 501
®
 and L. paracasei IMC 
502
®
 in the faeces of participants who consumed foods enriched with these strains were not 
considered by the Panel (Silvi et al., 2003; Cresci et al., 2004, 2005; Verdenelli et al., 2007, 2009).  
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of SYNBIO
®
, a combination of Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus 
paracasei IMC 502
®
, and maintenance of normal defecation. 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food, SYNBIO®, a combination of Lactobacillus rhamnosus IMC 501® and Lactobacillus 
paracasei IMC 502
®
, which is the subject of the health claim, is sufficiently characterised. 
 The claimed effect proposed by the applicant is “favouring the natural regularity and 
contributing to maintain and improve human intestinal well-being”. The target population 
proposed by the applicant is the healthy adult population. Maintenance of normal defecation 
is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of 
SYNBIO
®
, a combination of Lactobacillus rhamnosus IMC 501
®
 and Lactobacillus paracasei 
IMC 502
®
, and maintenance of normal defecation. 
DOCUMENTATION PROVIDED TO EFSA 
1. Health claim application on SYNBIO®, a combination of Lactobacillus rhamnosus IMC 501® 
and Lactobacillus paracasei IMC 502
®
, and maintenance of normal defecation pursuant to Article 
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ABBREVIATIONS 
CFU  colony-forming unit 
DSMZ  Deutsche Sammlung von Mikroorganismen und Zellkulturen 
